Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
WUXI BIO Launches Construction of Modular Biologics Drug Product Facilities at SG CRDMO Hub
Recommend 31 Positive 40 Negative 13 |
||||
|
||||
|
WUXI BIO (02269.HK) announced construction has recently begun for a new modular Drug Product (DP) facility, which will become part of its CRDMO hub in Singapore. Upon completion, the facility will be one of the world's largest modular biologics DP facilities, comprising approximately 30,000 square meters of space. It is anticipated to commence operations in 2027. The facility will feature state-of-the-art manufacturing lines, including three pre-filled syringe (PFS) production lines and two vial production lines for both liquid and lyophilized products. It will also feature centralized Quality Control (QC) labs supporting full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, which are expected to significantly enhance the Company's end-to-end DP services capabilities. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
